Apremilast - Amgen
Alternative Names: AMG-407; CC-10004; CC-1004; OTEZLALatest Information Update: 03 Oct 2024
At a glance
- Originator Celgene Corporation
- Developer Amgen; Baylor Research Institute; Celgene Corporation
- Class Acetamides; Anti-inflammatories; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Antivirals; Isoindoles; Phthalimides; Skin disorder therapies; Small molecules; Sulfones
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Behcet's syndrome; Plaque psoriasis; Psoriatic arthritis
- Phase III Juvenile rheumatoid arthritis; Palmoplantar pustulosis; Psoriasis
- Phase II Lichen planus
- Discontinued Ankylosing spondylitis; Asthma; Atopic dermatitis; Bullous pemphigoid; Cancer; COVID 2019 infections; Crohn's disease; Eczema; Hidradenitis suppurativa; Rheumatoid arthritis; Ulcerative colitis
Most Recent Events
- 30 Sep 2024 Discontinued - Phase-II for Atopic dermatitis (Combination therapy) in USA (PO) (Amgen pipeline, September 2024)
- 30 Sep 2024 Discontinued - Phase-II for Atopic dermatitis in Japan, Canada, USA (PO) (Amgen pipeline, September 2024)
- 30 Sep 2024 Discontinued - Phase-II for Bullous pemphigoid in Netherlands (PO) prior to September 2024 (Amgen pipeline, September 2024)